-

Exact Sciences to Participate in March Investor Conferences

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

  • TD Cowen Health Care Conference, Boston
    Fireside chat on Monday, March 3, 2025 at 10:30 a.m. ET
  • Raymond James Institutional Investors Conference, Orlando
    Presentation on Tuesday, March 4, 2025 at 1:05 p.m. ET

The webcasts can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Contacts

Derek Leckow
Exact Sciences Corp.
investorrelations@exactsciences.com
608-893-0009

Exact Sciences Corp.

NASDAQ:EXAS

Release Versions

Contacts

Derek Leckow
Exact Sciences Corp.
investorrelations@exactsciences.com
608-893-0009

More News From Exact Sciences Corp.

Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment process, advancing the field of MRD testing. The Oncodetect test delivers clear "De...

JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, “Genomic Assays for Breast Cancer in Diverse Populations: Prognostic and Predictive Insights,” affirms that the Oncotype DX test provides accurate and reliable information t...

Exact Sciences Schedules First Quarter 2025 Earnings Call

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursd...
Back to Newsroom